Perrigo claim Revenue's case against them is 'without merit'

A pharmaceutical company facing a €1.6 billion tax demand from Revenue, says it will fight the decision through all available avenues.

The assessment made against Elan Pharma relates to the amount of tax paid on the sale of its stake in the groundbreaking drug Tysabri.